Search
Praxis Precision Medicines Inc
PRAXAdd to Watchlist
282.310USD
+12.300+4.56%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
7.87BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Praxis Precision Medicines Inc is 8.33, ranking 137 out of 389 in the Biotechnology & Medical Research industry. The average price target is 340.00, with a high of 760.00 and a low of 65.00.
Analyst Rating
Based on
18
analysts
Buy
Current Rating
615.722
Target Price
+128.04%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Praxis Precision Medicines Inc
PRAX
18
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Praxis Precision Medicines Inc's price target?
Analysts forecast that Praxis Precision Medicines Inc's price target is USD 340.00, with the highest forecast at USD 760.00 and the lowest forecast at USD 65.00.
How have Praxis Precision Medicines IncPRAX's recent earnings per share performed?
The market expectation was USD -3.20, while Praxis Precision Medicines IncPRAX's earnings per share (EPS) for the previous quarter was USD -3.49. EPS for the next quarter is expected at USD -3.64.
What is the analyst rating for Praxis Precision Medicines Inc?
Based on the ratings of Praxis Precision Medicines Inc's stock from 18 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
